Prof Emili Montserrat talks to ecancer.tv about the development of the European Haematology Association congress and outlines some of the key research presented relating to chronic lymphocytic leukaemia (CLL). The use of rituximab in chemoimmunotherapy has dramatically improved survival in many CLL patients and results of maintenance therapy trials are showing that a cure for this disease may eventually be possible. Prof Montserrat concludes by discussing other options for CLL patients, such as biomarkers or the use of chlorambucil and explaining how clinical trials offer hope to patients who do not respond to existing therapies.